Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid ...

Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date ...

Update 1:25pm: Adds Jefferies analyst comment. Exelixis (NASDAQ:EXEL) rose 5% as the patent trial over its Cabometyx drug ended. Closing arguments took place in a Delaware court on Thursday ...

Commissions do not affect our editors' opinions or evaluations. Employees wearing custom T-shirts in-store or at events will promote your brand. You can also give customized T-shirts as ...

White T-shirts get a lot of attention, but let’s not forget their equally versatile counterpart: the exceedingly wearable, deceptively simple black T-shirt. It’s a staple you can wear to work ...

One of Ipsen’s flagship oncology assets Cabometyx (cabozantinib) will not be gaining an indication in prostate cancer outside the US or Japan after a Phase III trial failed to meet one of its ...

PARIS, FRANCE, 16 September 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today final data from the CABINET Phase III trial investigating Cabometyx ® (cabozantinib) versus placebo in people ...